Synopsys stock (SNPS) heads into 2026 down 1% — what traders watch next

Synopsys stock (SNPS) heads into 2026 down 1% — what traders watch next

NEW YORK, January 1, 2026, 17:06 ET — Market closed.

  • U.S. markets are closed for New Year’s Day; Synopsys last closed down about 1% at $469.72. Reuters
  • The stock has fallen for two straight sessions on light volume and sits about 28% below its 52-week high. MarketWatch
  • Focus shifts to tech risk appetite, Fed rate expectations, and Synopsys’ early-January CES appearance. Reuters+1

Synopsys shares last closed down about 1% at $469.72 on Wednesday, with U.S. markets shut on Thursday for the New Year’s Day holiday. Reuters

The move matters because the chip-design software group is being pulled between two forces: continued spending tied to artificial intelligence hardware and a late-year wobble in big tech that has investors reassessing positioning into 2026. Reuters+1

Synopsys is a key supplier of electronic design automation (EDA) software — tools engineers use to design and verify chips before they are manufactured — and it competes closely with Cadence Design Systems and Siemens in that market, Reuters reported. Reuters

Wall Street ended 2025’s final session lower in thin holiday trading, with the S&P 500 down 0.74% and the Nasdaq off 0.76%, Reuters said. Reuters

“It’s just a healthy rebalancing of allocations more so than an emotionally driven sell-off (in tech),” Mark Hackett, chief market strategist at Nationwide, said. Reuters

For Synopsys, Wednesday’s decline marked a second straight drop, with volume around 1.2 million shares — roughly 1 million below its 50-day average — MarketWatch reported. MarketWatch

The stock is about 28% below its 52-week high of $651.73, reached on July 30, and it outperformed some tech and chip-related names that fell more sharply on the day, the report said. MarketWatch

Rival Cadence also ended lower by roughly 1% at its last close, underscoring the sector-wide tone into year-end.

Company-specific catalysts remain anchored in December’s updates. Synopsys said it beat fourth-quarter revenue estimates and posted adjusted — or non-GAAP — profit that strips out certain items such as stock-based compensation; Reuters reported revenue of $2.26 billion and adjusted profit of $2.90 per share. Reuters

Synopsys also forecast first-quarter revenue of $2.36 billion to $2.42 billion, Reuters said, after it completed its acquisition of simulation-software maker Ansys in July — a deal that broadened its footprint beyond chip design. Reuters+1

Before Friday’s reopening, investors will watch whether tech stabilizes after a late-December slide and whether rate expectations reassert themselves. The Fed meets Jan. 27-28, and investors expect the central bank to leave rates unchanged, Reuters reported. Reuters+1

On the near-term calendar, Synopsys is scheduled to exhibit at CES 2026 in Las Vegas from Jan. 6-9, highlighting automotive engineering and systems-to-silicon tools, the company said. Synopsys News Releases+1

Traders will also watch for signs that integration costs and restructuring actions stay contained after Synopsys said it planned layoffs of about 10% of its workforce, and for any demand read-through tied to AI-driven chip complexity as 2026 trading ramps up. Reuters+1

Stock Market Today

  • CoreWeave's 2026 revenue surge eyed as potential driver for new highs amid IPO-era volatility
    January 1, 2026, 7:29 PM EST. Analysts expect CoreWeave to finish 2025 with about $5.1 billion in revenue and reach roughly $12 billion in 2026 as AI workloads push cloud capacity. CoreWeave offers turnkey, GPU-focused cloud infrastructure to AI hyperscalers; customers include Microsoft, Meta and IBM. The stock has fallen about 60% from its IPO peak and trades around $71.55 with a $36 billion market cap amid volatility. While growth prospects are solid, the company is pursuing heavy capital expenditure on GPUs and hardware, complicating a quick path to profitability. If demand scales as forecast, CoreWeave could test new highs by late 2026, but execution risk remains in a crowded cloud-AI race.
Axsome Therapeutics (AXSM) stock jumps after FDA sets April 30 decision for Alzheimer’s agitation drug
Previous Story

Axsome Therapeutics (AXSM) stock jumps after FDA sets April 30 decision for Alzheimer’s agitation drug

S&P Global (SPGI) stock ends 2025 down nearly 1% as markets shut for New Year’s — what to watch next
Next Story

S&P Global (SPGI) stock ends 2025 down nearly 1% as markets shut for New Year’s — what to watch next

Go toTop